Metabolic effects of metformin in patients with impaired glucose tolerance (Q43734822)

26 November 2017

title

Metabolic effects of metformin in patients with impaired glucose tolerance (English)

1 reference

26 November 2017

0 references

0 references

1 reference

7

Groop L

1 reference

26 November 2017

Marja-Riitta Taskinen

6

object named as

Taskinen MR

1 reference

26 November 2017

5

Eriksson JG

1 reference

26 November 2017

Lehtovirta M

1

1 reference

26 November 2017

Forsén B

2

1 reference

26 November 2017

Gullström M

3

1 reference

26 November 2017

Häggblom M

4

1 reference

26 November 2017

publication date

1 July 2001

1 reference

26 November 2017

1 reference

26 November 2017

volume

18

1 reference

26 November 2017

issue

7

1 reference

26 November 2017

page(s)

578-583

1 reference

Non-insulin-dependent diabetes mellitus--a collision between thrifty genes and an affluent society

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00539.X

Banting lecture 1988. Role of insulin resistance in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00539.X

Prospective analysis of the insulin-resistance syndrome (syndrome X).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00539.X

21 January 2018

Sulfonylureas in NIDDM.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00539.X

Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00539.X

Metabolic consequences of a family history of NIDDM (the Botnia study): evidence for sex-specific parental effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00539.X

Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00539.X

Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00539.X

Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00539.X

Thiazolidinediones in the treatment of insulin resistance and type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00539.X

Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00539.X

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00539.X

Metabolic effects of metformin in non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00539.X

Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00539.X

Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00539.X

Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00539.X

Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00539.X

Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00539.X

Metformin Enhances Clearance of Chylomicrons and Chylomicron Remnants in Nondiabetic Mildly Overweight Glucose-Intolerant Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00539.X

The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00539.X

Insulin action and substrate competition

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00539.X

Cellular mechanism of metformin action involves glucose transporter translocation from an intracellular pool to the plasma membrane in L6 muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00539.X

In vivo metformin treatment ameliorates insulin resistance: evidence for potentiation of insulin-induced translocation and increased functional activity of glucose transporters in obese (fa/fa) Zucker rat adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00539.X

The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00539.X

Metformin increases insulin sensitivity and basal glucose clearance in Type 2 (non-insulin dependent) diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00539.X

Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00539.X

Effect of metformin on patients with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00539.X

The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00539.X

The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.2001.00539.X

10.1046/J.1464-5491.2001.00539.X

21 January 2018

Identifiers

DOI

1 reference

26 November 2017

1 reference